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A new concept for 
enhancing cardioplegic 
protection? 
Ischemic preconditioning defines an adaptive ndogenous mechanism inwhich 
a brief episode of reversible ischemia renders the heart more resistant to a 
subsequent period of sustained ischemia. Because the cardioprotective effects 
of ischemic preconditioning might be mediated by an activation of adenosine 
triphosphate-sensitive potassium channels, this study was designed to assess 
whether these effects could be duplicated by the preischemic administration of
a potassium channel opener. Fifty isolated isovolumic buffer-perfused rat 
hearts underwent 45 minutes of normothermic potassium arrest followed by 1 
hour of reperfusion. They were divided into five equal groups that differed with 
regard to the preconditioning re imen: Group 1 hearts were left untreated and 
served as controls; in group 2, preconditioning was achieved with 5 minutes of 
total global ischemia followed by 5 minutes of buffer reperfusion before 
cardioplegic arrest; in group 3, the preconditioning stimulus consisted of a 
5-minute infusion of the potassium channel opener nicorandil (10 #tool/L) 
followed by 5 minutes of drug-free buffer perfusion before arrest; group 4 
hearts underwent a similar protocol except hat the infusion of nicorandil was 
preceded by that of the potassium channel blocker glibendamide (10 ~mol/L); 
group 5 hearts were ischemically preconditioned like those of group 2 except 
that the no-flow preconditioning period was also preceded by a 5-minute 
infusion of glibendamide (50 pmol/L). The results demonstrate hat ischemic 
preconditioning significantly improved contractility and reduced contracture 
during reperfusion, as compared with results in control hearts. These protec- 
tive effects were duplicated by pretreatment with nicorandil but were abolished 
when the drug was antagonized by a prior infusion of glibenclamide. Likewise, 
the glibenclamide-induced blockade of potassium channels largely blunted the 
beneficial effects of ischemic preconditioning. These data suggest that opening 
of adenosine triphosphate-sensitive potassium channels ubstantially contrib- 
utes to preconditioning-induced cardiac protection in a surgically relevant 
model of global ischemia and, consequently, that the use of potassium channel 
openers like nicorandil could be an effective means of enhancing cardioplegic 
protection. (J THORAC CARDIOVASC SURG 1995;110:1606-14) 
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schemic preconditioning defines an adaptive 
mechanism by which a short period of ischemic 
stress increases the resistance of the myocardium to 
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a subsequent, more prolonged period of that same 
stress. 1Although the efficacy of this form of endog- 
enous myocardial protection has now been docu- 
mented by a large number of experimental studies, 
its mechanism is not yet fully characterized. Never- 
theless, one of the currently prevailing hypotheses i  
that ischemic preconditioning could be mediated in 
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part by endogenously released adenosine and a 
subsequent adenosine-induced activation of adeno- 
sine triphosphate (ATP)-sensitive potassium chan- 
nels.2, 3 The therapeutic exploitation of the precon- 
ditioning phenomenon is an appealing prospect in 
cardiac surgery, because the possibility of planning 
the onset of the ischemic period induced by aortic 
crossclamping should allow a timely appropriate 
implementation of the preconditioning stimulus. 
However, in a clinical perspective, a pharmacologic 
induction of preconditioning would have obvious 
advantages in terms of safety and practicality over 
an induction regimen of the ischemic type. Conse- 
quently, the present study was designed to assess 
whether the protective ffects of ischemic precondi- 
tioning could be mimicked by the administration of 
a potassium channel opener in a surgically relevant 
model of cardioplegic arrest. 
Methods 
Experimental preparation. Fifty male Wistar rats 
weighing 300 gm were anesthetized intraperitoneally with 
pentobarbital (180 rag). All animals received human care 
in compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985). The animals were given 0.2 ml heparin intrave- 
nously; the hearts were then quickly excised and mounted 
on a nonrecirculating Langendorff perfusion column. 
Retrograde aortic perfusion was instituted at a pressure 
of 100 cm HaO with filtered Krebs-Henseleit solution (in 
millimoles per liter: NaC1, 118; KCI, 4.7; MgSO4, 1.2; 
NaHCOa, 25; KH2PO 4, 1.2; CaC12, 2.5; glucose, 11) gassed 
with a mixture of 95% oxygen and 5% carbon dioxide. Both 
the column and the hem't chamber were enclosed in a water 
jacket so as to maintain myocardial temperature at 37 ° C 
throughout the experimental time course. 
Functional measurements. A latex balloon was in- 
serted into the left ventricle and connected through 
fluid-filled polyethylene tubing (inner diameter 1mm) to 
a pressure transducer (P23ID, Gould, Inc., Cleveland, 
Ohio). Output from the pressure transducer was differen- 
tiated electronically (model 13-4615-71, Gould) to record 
maximum rate of rise of left ventricular pressure (dP/dt). 
End-diastolic pressure was set to approximately 10 mm 
Hg by filling the left ventricular balloon with 80 to 110/xl 
of perfusate. Developed pressure was measured as the 
difference between peak systolic pressure and end-dia- 
stolic pressure. All pressure and dP/dt signals were dis- 
played on a Schlumberger OM-4502 four-channel direct- 
writing recorder (Enertec, St. Etienne, France). Coronary 
flow was measured by timed collection of the coronary 
venous effluent. Left ventricular pacing was maintained at 
a rate of 320 beats/min throughout he control and 
reperfusion periods. 
Experimental protocol. Hearts were allowed to recover 
for 15 minutes after being instrumented and stable hemo- 
dynamic recordings were established. All hearts were then 
subjected to 45 minutes of normothermic potassium arrest 
followed by 60 minutes of reperfusion. Initial asystole was 
achieved by adding concentrated potassium chloride di- 
rectly to the Krebs perfusate (to a final concentration of
approximately 20mEq/L), after which hearts were main- 
tained in a globally ischemic state for the remainder of the 
arrest period. The left ventricular balloon was kept in- 
flated throughout his period at the same volume as 
during the control period, which allowed on-line monitor- 
ing of ischemic ontracture. 
The hearts were divided into five groups of 10 each, 
which differed only in the treatment administered be- 
fore cardioplegic ischemia. Group 1 consisted of con- 
trol hearts that underwent no manipulations during the 
preischemic period. In group 2, hearts were precondi- 
tioned with 5 minutes of global total (no flow) ischemia 
followed by 5 minutes of reperfusion with the Krebs 
buffer before the onset of cardioplegic arrest. In group 
3, the preconditioning regimen consisted of a 5-minute 
period of administration of the potassium channet 
opener nicorandil (10/zmol/L) followed by 5 minutes of 
perfusion with drug-free buffer before cardioplegic 
arrest. This concentration of nicorandil was selected 
after preliminary dose-response experiments had estab- 
lished that it exerted cardioprotective effects without 
significantly affecting prearrest hemodynamic variables. 
Group 4 hearts underwent a protocol similar to that 
used in group 3 except that the administration of 
nicorandil was preceded by that of the potassium 
channel blocker glibenclamide (10 /~mol/L) over a 
5-minute period. In group 5, hearts were ischemically 
preconditioned as in group 2 but also received gtiben- 
clamide (50/xmol/L) for 5 minutes before the 5-minute 
no-flow preconditioning challenge. These various pro- 
tocols are depicted in Fig. 1. 
Functional measurements were taken during the con- 
trol period, both before and after the various ischemic and 
pharmacologic interventions. Measurements were re- 
peated at 15, 30, 45, and 60 minutes of reperfusion. 
During arrest, maximal isovolumic diastolic pressures and 
the time required to achieve these peak contractures were 
recorded in all hearts. 
Nicorandil was supplied by Rhone-Poulenc Rorer 
(Antony, France) and glibenclamide was purchased from 
Sigma Chemical Co. (St. Louis, Mo.). Both drugs were 
dissolved in Krebs buffer immediately before use and 
delivered into the aortic root at a pressure of 100 cm HzO 
via a separate column. 
Statistical analysis. Statistical analysis was performed 
with two-way analysis of variance with repeated mea- 
sures and Student's t test, where appropriate. Ap  value 
of less than 0.05 was considered significant. All results 
are expressed as means + the standard error of the 
mean. 
Results 
Prearrest data. Analysis of variance indicated no 
significant between-group differences for any pa- 
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Fig. 1. Experimental time course. PC, Preconditioning. 
Table I. Baseline data for the five experimental 
groups 
Preconditioning Coronary Diastolic 
regimen flow pressure LV dP/dt 
(n = 10) (ml/min) (ram Hg) (ram Hg/sec 1) 
None (controls) 15.8 -+ 0.4 9.6 _+ 0.6 4745 + 170 
Zero-flow ischemia 16.0 +_ 0.3 9.2 _+ 0.7 4570 _+ 167 
Nicorandil 15.3 ~ 0.6 9.1 + 0.3 4767 +_ 161 
Glibenclamide+nicorandil 15.1 -+ 0.6 11.3 + 0.9 5002 + 117 
Glibenclamide+zero- 15.1 _+ 0.4 10.2 +_ 0.4 4770 + 96 
flow ischemia 
rameter before arrest (Table I). Therefore baseline 
data depicted in Figs. 2 and 3 are pooled group 
averages. 
Ischemic preconditioning resulted in a slight, but 
significant, decline in contractile function, as evi- 
denced by a decrease in dP/dt values from 4570 +_ 
167 mm Hg/sec -~ before the 5-minute period of 
no-flow ischemia to 4065 _+ 146 mm Hg/sec -~ after 
the ischemic hallenge (p < 0.03). Conversely, he- 
modynamic values recorded after nicorandil pre- 
treatment were unchanged from baseline data col- 
lected before drug infusion. The greatest declines in 
coronary flow (shown in Table II) and left ventric- 
ular function were seen in the two glibenclamide- 
pretreated groups. The dP/dt fell from 5002 + 117 
mm Hg/sec -~ before the preconditioning sequence 
to 3105 +_ 216 mm Hg/sec -~ after the sequence (p < 
0.0001) in the glibenclamide-nicorandil group and 
from 4770 +_ 96 mm Hg/sec -1 to 2905 _+ 152 mm 
Hg/sec -1 (p < 0.0001) in the glibenclamide-zero- 
flow ischemia group. In none of these two groups, 
however, did diastolic pressure measured after pre- 
conditioning significantly change compared with the 
baseline value. 
Arrest data. The most effective limitation of isch- 
emic contracture was achieved with nicorandil pre- 
conditioning, which yielded peak diastolic pressures 
significantly lower than those of the four other 
groups (Table III). These protective ffects of po- 
tassium channel opening were mirrored by the det- 
rimental effects of potassium channel blockade. 
Thus glibenclamide pretreatment before ischemic or 
nicorandil preconditioning resulted in a significant 
increase in diastolic pressures during arrest com- 
pared with each of these preconditioning regimens 
alone. 
In keeping with these observations, both ischemic 
and nicorandil preconditioning lengthened the time 
to peak contracture, although the difference with 
control hearts attained statistical significance only 
for the drug-pretreated hearts (see Table III). 
Again, the detrimental effects of blocking potassium 
channels were demonstrated by the finding that 
administration of glibenclamide before ischemic 
(group 5) or nicorandil (group 4) preconditioning 
significantly shortened the time to peak contracture 
compared with the corresponding control values 
(groups 2 and 3, respectively). Indeed, the worst 
results were seen in the glibenclamide+ischemia 
preconditioning protocol, which was associated with 
a time to peak contracture that was even shorter 
than in control untreated hearts. 
Postarrest data 
Coronary flow. Results are summarized in Table 
II. The greatest postischemic coronary flows were 
found in hearts that had undergone ischemic pre- 
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Fig. 2. Effects of different preconditioning (PC) regimens on isovolumic diastolic pressures. Reperfusion 
values represent the average of d ta recorded over the 60-minute ischemic period that followed 45 minutes 
of normothermic potassium arrest. Data points are arithmetic means + 1 standard error of the mean, 
obtained with 10 hearts per group. 
conditioning (group 2). Although nicorandil pre- 
treatment was associated with significantly lower 
values (p < 0.005 versus group 2), the contribution 
of potassium channel opening to preconditioning- 
induced cardiac protection is suggested by the ob- 
servation that blockade of this opening by gliben- 
clamide before ischemic preconditioning resulted in 
a significant (p < 0.0001) reduction in postischemic 
coronary flow, as compared with ischemic precondi- 
tioning alone. Likewise, hearts that were treated 
with glibenclamide b fore nicorandil had signifi- 
cantly (p < 0.0001) lower postarrest coronary flows 
than those in which the potassium channel opener 
had been given alone. 
Left ventricular diastolic pressure. Pooled pre- 
reperfusion and postreperfusion values for diastolic 
pressure are depicted in Fig. 2. Both ischemic and 
nicorandil preconditioning resulted in an almost 
twofold reduction in postischemic contracture, as 
compared with control hearts that were not precon- 
ditioned. However, this protective ffect was largely 
lost when either of these two preconditioning regi- 
mens was preceded by a glibenclamide-induced 
blockade of potassium channels. Group 4 hearts 
(glibenclamide-nicorandil) were then found to incur 
losses of diastolic function similar to those of un- 
treated hearts, in contrast to group 5 hearts (gliben- 
clamide-ischemic preconditioning), which had post- 
arrest diastolic pressures till slightly lower than 
those of control hearts (p < 0.01 between groups 5 
and 1). 
Left ventricular function. As shown in Fig. 3, 
preconditioning, whether induced by a brief period 
of no-flow ischemia or a nicorandil pretreatment of 
similar duration, significantly improved the recovery 
of dP/dt over the entire reperfusion period, as 
compared with recovery of untreated hearts. This 
improvement was of similar magnitude in the two 
preconditioned groups. In keeping with data on 
diastolic function, blockade of potassium channels 
by glibenclamide significantly decreased the recov- 
ery of contractile function in both ischemically and 
pharmacologically preconditioned hearts (as it did 
in a separate group of experiments (data not 
shown), in which it was used alone, that is, without 
subsequent preconditioning). However, whereas 
glibenclamide ahnost completely blocked the pro- 
tective effects of nicorandil pretreatment, i  abol- 
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Fig. 3. Effects of different preconditioning (PC) regimens on isovolumic left ventricular dP/dt (LV dP/dt). 
Reperfusion values represent the average of data recorded over the 60-minute postischemic period that 
followed 45 minutes of normothermic potassium arrest. Data points are arithmetic means + 1 standard error 
of the mean, obtained with 10 hearts per g oup. 
ished those of ischemic preconditioning to a lesser 
extent. Thus glibenclamide pretreatment followed 
by ischemic preconditioning yielded a recovery that 
was roughly intermediate between that of control 
hearts and that of hearts subjected to ischemic 
preconditioning alone, thereby suggesting that the 
latter challenge involves other protective mecha- 
nisms than opening of ATP-sensitive potassium 
channels. 
The recovery patterns of left ventricular devel- 
oped pressure paralleled those of dP/dt. 
Discussion 
Preconditioning in the setting of cardiac surgery. 
As previously mentioned, the efficacy of ischemic 
preconditioning asa means of attenuating myocar- 
dial injury caused by a subsequent episode of pro- 
longed ischemia has been demonstrated in several 
animal studies, but most of them have actually been 
performed in regionally ischemic preparations and 
have used infarct size and arrhythmias as primary 
end points. It is therefore interesting to note that, 
more recently, evidence has been brought hat the 
preconditioning phenomenon could also pertain to 
global myocardial ischemia nd was then reflected 
by an improved recovery of function during reper- 
fusion. 4-6 
This assumption is supported by the results of the 
present study. Thus hearts ubjected to 5 minutes of 
no-flow ischemia before the sustained period of 
cardioplegic arrest had a better tolerance to isch- 
emia than their nonpreconditioned counterparts, as
demonstrated by a lesser degree and a delayed onset 
of contracture during arrest and an improved recov- 
ery of function during reperfusion. 
These results support the clinical findings of 
Alkhulaifi and coworkers, 7 who have shown in pa- 
tients undergoing coronary artery bypass grafting 
that two 3-minute periods of aortic crossclamping 
separated by 2 minutes of reperfusion before a 
10-minute period of global ischemia under hypo- 
thermic ventricular fibrillation were associated with 
a better preservation of myocardial ATP levels. 
Interestingly, the protection afforded by precondi- 
tioning in the setting of global ischemia seems to 
remain operative under the surgically relevant con- 
ditions of hypothermic schemia 4 and cold cardio- 
plegia. 6Only a recent study areported that ischemic 
preconditioning did not improve functional recovery 
after 2 hours of multidose cold crystalloid cardiople- 
gia. However, analysis of the data presented in this 
paper suggests that hearts preconditioned with 5 or 
10 minutes of global ischemia indeed had a better 
tolerance for arrest han the control hearts in that 
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Table II. Effects of different preconditioning 
regimens of coronary flow 
Coronary flow (ml/min) 
Baseline 
Preconditioning 
regimen Before After 
(n = 10) treatment treatment Reperfusion 
None (controls)  15.8 + 0.4 - -  13.6 -+ 0.3 
Zero - f low ischemia 16.0 ± 0.3 15.5 -+ 0.4 15.3 ± 0.35 
N icorandi l  15.3 + 0.6 15.3 + 0.6 13.9 _+ 0.3 
G l ibenc lamide+nicorand i l  15.1 + 0.6 12.2 ± 0.9* 8.8 _+ 0.3§ 
G l ibenc lamide+zero -  15.1 ± 0.4 12.6 ± 0.85 10.9 -+ 0.3]1 
f low ischemia 
Baseline prearrest values were recorded before the preconditioning inter- 
vention, after stabilization of the preparation, and after the precondition- 
ing intervention, during the 5 minutes of standard Krebs buffer perfusion 
that preceded the onset of cardioplegic arrest. Hearts were then main- 
tained in an arrested ischemic state for 45 minutes at 37 ° C. Reperfusion 
values are pooled data over the 60-minute ischemic period. Values are 
arithmetic means -+ I standard error of the mean. 
*p < 0.003 versus the corresponding pretreatment value. 
tp < 0.009 versus the corresponding pretreatment value. 
Sp < 0.005 versus the nicorandiI group. 
§p < 0.000I versus the nicorandil group. 
liP < 0.0001 versus the zero-flow ischemia group. 
they were able to achieve similar postischemic levels 
of contractility at the expense of twofold lower 
diastolic pressures. 
Link between preconditioning and opening of 
potassium channels. Although the mechanism of 
preconditioning remains incompletely understood, an 
important role is attributed to an activation of the A 1 
adenosine receptors, which would subsequently evoke 
a G protein-mediated translocation of protein kinase 
C to the membrane, where it becomes active. 9 The 
ATP-sensitive potassium channel is one of the cellular 
components hat might be phosphorylated by protein 
kinase C and, as such, has been proposed as a possible 
effector of this cellular signaling pathway. 
This hypothesis i primarily based on the obser- 
vation made in several species, including pig, rabbit, 
and dog, that the protection afforded by precondi- 
tioning can be equally achieved bypotassium chan- 
nel openers whereas it is abolished by potassium 
channel blockers. 2'3, 10 Our data extend these obser- 
vations to the setting of global ischemia in rat hearts 
by demonstrating that a 5-minute infusion of nie- 
orandil completely mimicked the protective ffects 
of an ischemic preconditioning stimulus of similar 
duration on functional recovery after an extended 
period of normothermic cardioplegic arrest. 
Previous studies have already documented the 
beneficial effects of potassium channel openers 
given as pretreatments before episodes of global 
Table III. Effects' of different preconditioning 
regimens on contracture during cardioplegic arrest 
(45 minutes at 37 ° C) 
Time to 
Preconditioning Peak peak 
regimen contracture contracture 
(n = 10) (ram Hg) (sec) 
None (controls)  51.8 + 3.0 1808 _+ 91 
Zero - f low ischemia 50.0 + 2.8 1978 _+ 132 
Nicorandi l  40.4 ± 2 .1"?  2068 -+ 45§11 
Gl ibenc lamide+nicorand i l  51.1 + Z8  1501 _+ 162 
G l ibenc lamide+zero - f low 57.7 __+ 3,0.~ 1421 ± 69¶ 
ischemia 
Values are arithmetic means ± 1 standard error of the mean, 
*p < 0.01 versus the control, zero-flow ischemia and glibenclamide+ 
nicorandil groups. 
tp < 0.0001 versus the glibenclamide+zero-flow ischemia group. 
~:p < 0.02 versus the zero-flow ischemia group. 
§p < 0.01 versus the control and glibenclamide+nicorandil groups. 
lip < 0.0001 versus the glibenclamide+zero-flow ischemia group. 
~lp < 0.001 versus the zero-flow ischemia group. 
ischemia.11, ,2 The present data, however, provide 
stronger evidence for a mechanistic link between 
preconditioning and opening of potassium channels 
and are thus consistent with the observations of Guo 
and coworkers, 5 who have shown that pretreatment 
with the potassium channel opener aprikalim pre- 
served left ventricular function to the same xtent as 
did ischemic preconditioning in isolated rat hearts 
undergoing 30 minutes of unprotected global isch- 
emia. In this study, the common protective mecha- 
nism shared by both ischemic preconditioning and 
aprikalim pretreatment was identified as an extra- 
cellular accumulation of potassium ions before the 
sustained episode of ischemia. Altogether, these 
data may appear to be at variance with those of Liu 
and Downey, 13 who have reported that pharmaco- 
logic blockade of potassium channels by gliben- 
clamide failed to abolish the protective effects of 
ischemic preconditioning in the rat and concluded 
that opening of potassium channels was therefore 
unlikely to mediate the phenomenon i this species. 
In contrast, the data of Guo and colleagues, s as well 
as our data, show that a pharmacologic blockade of 
potassium channels results in a dramatic reduction 
of the cardioprotective effects of ischemic precondi- 
tioning. Interestingly, a similar phenomenon has 
been reported in patients receiving glibenclamide 
before coronary angioplastyJ 4 Actually, several dif- 
ferences in the experimental design may account for 
these discrepant results, in particular the use, in the 
study of Liu and Downey, I3 of a regionally ischemic 
preparation of infarct size (as opposed to recovery 
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of function) as the primary end point and of much 
lower doses of glibenclamide, as compared with our 
study and those of Guo and associates, s Further- 
more, the fact that glibenclamide was quite effective 
in abolishing the protective effects of nicorandil 
preconditioning in the present s udy provides addi- 
tional evidence that the drug-induced improvement 
in myocardial protection was primarily due to po- 
tassium channel opening and not to nitrovasodila- 
tory effects, is The direct cytoprotective effects of 
nicorandil are also supported by the Observation 
ttiat its administration failed to affect coronary flow 
significantly dUring the prearrest period. The dose 
of l0/xmol/L was used in the glibenclamide-nicoran- 
dil group because both literature data 11 and per- 
sonal dose-response tudies uggest that the effects 
of potassium channel openers can be antagonized 
on an equimolar basis. In the glibenclamide-isch- 
emic preconditioning group, the dose of 50/xmol/L 
was selected to allow comparison with the results of 
GUO and coworkers, 5 who have used this concentra- 
tion Of the potassium channel in a protocol of precon- 
ditioning similar to ours (5 minutes of ischemia nd 5 
minutes of reperfusion before the sustained episode of 
ischemia). This high concentration is consistent with 
the possibility that the ability of glibenclamide to block 
potassium channels is reduced during ischemia, is so 
that such a blockade requires higher doses of this 
compound than those that are effective in the presence 
of a potassium channel opener (without superimposed 
ischemia, as in our group 4). 
However, the finding that glibenclamide com- 
pletely abolished the cardioprotective effects of nic- 
orandil whereas it only partially blunted those of 
ischemic preconditioning suggests that the protec- 
tive mechanisms of this latter mode of precondition- 
ing extend beyond the sole opening of ATP-sensitive 
potassium channels. This indeed consistent with 
the observation that, similar to what has been de- 
scribed in the rabbit, 9preconditioning in the rat also 
seems to be mediated by activation of protein kinase 
C, 16 whose target proteins for phosphorylation are 
not restricted to those making up the potassium 
channel. 
The mechanism whereby opening of potassium 
channels may provide improved myocardial protec- 
tion is not yet fully elucidated. It is, however, likely 
that this mechanism primarily involves a reduction 
Of the inward calcium current through voltage- 
operated sarcolemmal channels subsequent to an 
attenuation of membrane depolarization. ~s-lv This 
should result in a limitation of calcium overload and 
a sparing of tissue energy stores 2 which, in turn, 
could account for the attenuation of contracture 
seen in our nicorandil-preconditioned hearts and 
also reported in globally isehemic rat s, 19 and rabbits 
hearts 17 exposed to aprikalim before the ischemic 
interval. These mechanisms could alsoexplain the 
efficacy of potassium channel openers when given 
either as additives to TM 12, !8 or even as substitutes 
for potassium 17in cardioplegic solutions. Whether 
the mitochondrial ATP-sensitive potassium chan- 
nel 2° can further contribute to preserve cytosolic 
calcium homeostasis still must be determined. Re- 
gardless of the exact mechanism by which potassium 
channel openers reproduce the cardioprotective ef- 
fects of ischemic preconditioning, the mechanism by 
which the cell keeps the "memory" of its brief 
exposure to nicorandil or other related drugs also 
remains to be explained. Sustained opening of po- 
tassium channels and decreased threshold for their 
activation during the ensuing period of protracted 
ischemia are among the possibilities that warrant 
further investigation. 
Clinical implications. The results of this study 
suffer from several methodologic limitations, includ- 
ing the use of an isolated heart preparation, the 
crystalloid nature of the perfusate, maintenance of 
normothermia during arrest, and the potential for 
subendocardial njury resulting from the presence of 
the inflated balloon within the left ventricular cavity 
throughout the period of ischemia. 
Despite these caveats, it is noteworthy that the 
protection yielded by nicorandil preconditioning 
was achieved according to a clinically relevant pro- 
tocol. Consequently, additional experimental in vivo 
studies seem to be warranted. Should their results 
confirm those reported herein, pharmacologic pre- 
conditioning with a potassium channel opener might 
become an effective adjunct to current myocardial 
protection strategies. Beyond the presumed interest 
of potassium channel openers, the results of this 
study also emphasize the potential benefits of ex- 
ploiting the heart's natural protective mechanisms 
for improving myocardial tolerance to surgically 
induced ischemic arrest. 
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Discussion 
Dr. Andrew S. Wechsler (Richmond, Va.). Events that 
trigger secondary messengers involved in preconditioning 
are both physical and chemical, and potassium channel 
openers are among the putative agents capable of simu- 
lating specific events during ischemia. In this case, the 
event is altered conductance of potassium that results in 
cell hyperpolarization and collapse of the action potential 
with limitation of calcium entry into the cell during the 
plateau phase of the action potential. Presumably this 
sequence of events mimics endogenous cell protective 
events during ischemia, fools the cell, serves as a urrogate 
for an ischemic episode, and triggers secondary messen- 
gers responsible for the preconditioning response. 
Dr. Menasch6, you have tested this hypothesis nicely, 
but a couple of questions remain. First, did you notice any 
difference in the time to electrical or mechanical arrest 
among the groups? Dr. Damiano and his colleagues atour 
institution have d monstrated persistence of depolariza- 
tion potentials long into the ischemic period after treat- 
ment with aprikalim or nicorandil, although these spikes 
are not associated with mechanical activity. 
Second, critical to your studies is an absence of any 
residual effect of the potassium channel opener immedi- 
ately before and during the ischemic interval. What 
evidence do you have that the potassium channel effect is 
completely gone after the 5-minute washout interval? This 
is obviously of importance because, if the channel is still 
partially open, one is studying the protective ffects of 
potassium channel openers rather than the effects of 
preconditioning. 
Dr. Menasch6. There was absolutely no difference in 
the time to arrest between the different groups. In 
Dr. Damiano's study, so far as I remember, the potassium 
channel openers were actually used for inducing arrest. 
This is a different approach from the one used in our 
study, in which t e potassium channel opener was given 
before the onset of cardioplegic arrest. This cardioplegic 
arrest was actually induced by potassium chloride, which 
caused immediate asystole, within a few seconds, in all 
groups. 
Regarding your second question: On the basis of what is 
known about he pharmacokinetics ofnicorandil, most of 
the drug, if not all, would be expected to have been 
washed out during the 5-minute period of intervening 
reperfusion between the end of drug delivery and the 
onset of cardioplegia. 
If we assume that one of the primary mechanisms by 
which ischemic preconditioning protects the heart is the 
opening of these potassium channels, I wonder if it is 
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important whether the channels remain open because 
some residual drug remained within the heart or just 
because they are open as a consequence of a second or 
third intracellular messenger, the initial release of which 
was caused by exposure of the heart to nicorandil. Again, 
however, given the pharmacokinetics of the drug, almost 
all of this drug is expected to have been washed out by the 
time cardioplegic arrest was started. 
Dr. Robert M. Mentzer, Jr. (Madison, Wis.). Your 
presentation brings to our attention the potential impor- 
tance of potassium channel openers in providing myocar- 
dial protection during cardiac operations. I am concerned, 
however, about the use of the term '°preconditioning" in 
the clinical setting, because the role of preconditioning, if 
any, in protecting the human heart against ischemic 
damage remains to be determined. You have nicely 
demonstrated that ischemic preconditioning can attenu- 
ate myocardial stunning in the rat and that inhibition of 
the potassium channel opener obviates the salutary effect. 
On the other hand, ischemic preconditioning is generally 
recognized to protect he heart via infarct size limitation 
and not attenuation of stunning. Although attenuation of 
stunning has been reported in the rat, this has not been 
confirmed in other animal species. In fact, there is con- 
siderable controversy as to whether ischemic precondi- 
tioning affects stunning in in vivo experiments. My ques- 
tion is this: Did you measure infarct size in these rat hearts 
in addition to assessing recovery of developed pressure, 
and what was the effect, if aw, of the potassium channel 
opener on infarct size reduction in the rat? 
Dr. Menasch& In this particular study we did not 
evaluate infarct size. The potassium channel hypothesis 
came from studies dealing with models of regional isch- 
emia in which potassium channel openers were able to 
completely duplicate the protective ffects of ischemic 
preconditioning on infarct size. Actually, this provided the 
starting point for us to assess whether the protection that 
had been demonstrated in these regionally ischemic prep- 
arations with infarct size as the main end point could be 
extended to the field of global ischemia with function as 
an end point. I acknowledge, however, that in the absence 
of histologic assessment, we cannot exclude that the 
improvement of stunning seen in this study was mediated 
by a reduction in infarct size. 
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